Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

Candel Therapeutics Inc. shares gained momentum as Wall Street analysts highlighted the potential of its lead cancer drug ...

Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Equities researchers at StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) in a report released on Saturday. The brokerage set a “sell” rating on the ...

Scale Biosciences (Scale Biotm), a leader in innovative and scalable single cell analysis solutions, today announced the availability of its QuantumScale Single Cell RNA kits, a set of next-generation ...

Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTACtm (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced ...

The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trial ...

The U.S. stock market took a hit on Friday as a wave of troubling economic news sent all major indexes tumbling. The S&P 500 suffered its worst drop in two months, sinking 1.7%, while the Dow and ...

Tinubu, APC leaders have settled on the removal of both Obasa and Meranda as House Speakers to solve the Lagos Assembly ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.